MOUD Buprenorphine Sublocade denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Sublocade — and How to Navigate It

A prior-authorization (PA) denial for Sublocade means the claim was processed without the required advance approval, or that the PA request was submitted but did not satisfy all of UnitedHealthcare's documented criteria. PA for extended-release injectable buprenorphine is common; it does not mean the drug will ultimately be denied. A well-prepared PA submission — or a targeted appeal of a PA denial — resolves the majority of these cases.

## Why PA Denials Are Appealable

If the PA was denied on clinical grounds (rather than a pure administrative failure to submit), you have full federal appeal rights. UHC's PA criteria must align with evidence-based clinical standards. A determination that a patient does not meet criteria for an FDA-approved MOUD product is a medical-necessity determination subject to internal and external review.

Federal parity law (MHPAEA) also requires that any PA requirements for substance use disorder treatment be no more burdensome than those for analogous medical/surgical benefits. If UHC applies more intensive PA requirements to OUD medications than to comparable chronic-condition medications, that is a parity violation.

## Your Federal Appeal Rights

• Peer-to-peer review: Before filing a formal appeal, request a peer-to-peer call between the prescriber and UHC's medical director. This is often the fastest route to overturning a PA denial.
• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on the denial letter. Attach all clinical documentation.
• External review: After internal exhaustion, request independent external review under ACA §2719 — typically within four months of the internal denial notice.
• Expedited PA / urgent appeal: If the patient's clinical situation is urgent, the prescriber can request expedited PA processing or an expedited appeal, typically resolved within 72 hours.

## Concrete Appeal Steps

1. Obtain the PA denial letter and identify exactly which criteria were listed as unmet. 2. Pull UHC's published PA criteria for Sublocade from uhcprovider.com — every criterion will be listed. 3. Request a peer-to-peer review call immediately. 4. Have the prescriber prepare a targeted letter addressing each unmet criterion with specific chart evidence. 5. Compile the full documentation package and file the internal appeal if the peer-to-peer does not resolve it.

## Documentation to Gather

• Diagnosis confirmation: DSM-5 moderate-to-severe OUD diagnosis with assessment date.
• Prior treatment history: Dates, formulations, outcomes, and reasons for transition for all prior MOUD treatment — including any sublingual buprenorphine trial history with adherence notes.
• Clinical severity: Current prescriber assessment notes documenting disease severity and clinical rationale for injectable formulation.
• Prescriber medical-necessity letter: Directly addressing each PA criterion listed by UHC, citing the FDA-approved prescribing label for the product's eligibility criteria and referencing ASAM/SAMHSA guidelines by organization name.
• Criteria-mapping table: One row per UHC PA criterion; one column for the chart evidence or prescriber attestation that satisfies it.

## Criteria-Mapping Structure

PA criteria for Sublocade commonly address diagnosis, prior treatment, and provider qualifications. Map each requirement explicitly. Reviewers process high volumes — a table format that answers every criterion in parallel columns is far more effective than a narrative letter alone.